Biotechnology News and Research

RSS

VeriStrat test may be useful for NSCLC clinical decision-making

Results from the combined analysis of two European Phase II trials were presented today at the 3rd European Lung Cancer Conference in Geneva, Switzerland. The VeriStrat retrospective analysis was performed on serum samples from advanced non-squamous non-small cell lung cancer (NSCLC) patients treated with the combination therapy bevacizumab plus erlotinib.

21 Apr 2012

LifeMap Sciences, BioTime to acquire XenneX

BioTime, Inc. and its wholly owned subsidiary LifeMap Sciences today announced that they have signed a definitive agreement to acquire XenneX, Inc. through a merger of XenneX into LifeMap Sciences. The acquisition is expected to close within thirty days.

21 Apr 2012

Positive results from Alnylam’s ALN-PCS Phase I trial on severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive results from its Phase I clinical trial of ALN-PCS, an RNAi therapeutic targeting PCSK9 for the treatment of severe hypercholesterolemia.

21 Apr 2012

ACT announces dosing of third patient in dry AMD Phase I/II trial

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today the dosing of the third patient in its Phase I/II trial for dry age-related macular degeneration (dry AMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells.

21 Apr 2012

Chinese scientists make significant breakthrough in animal cloning

Chinese scientists from BGI, the world's largest genomics organization, together with the Institute of Genetics and Developmental Biology, Chinese Academy of Sciences (CAS), and Shihezi University, Xinjiang province, made a significant breakthrough in animal cloning.

20 Apr 2012

Palatin, AstraZeneca initiate second AZD2820 phase I trial in obesity

Palatin Technologies, Inc. today announced that a second phase I clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist under development for the treatment of obesity, has commenced.

20 Apr 2012

New studies on personalized lung cancer treatment presented at 3rd ELCC

Several new studies that may help doctors tailor lung cancer treatment to the characteristics of individual patients and of their tumors are being presented at the 3rd European Lung Cancer Conference in Geneva.

19 Apr 2012

FDA's three draft guidances on biosimilars - BIO submits comments

The Biotechnology Industry Organization (BIO) submitted comments yesterday to the U.S. Food and Drug Administration (FDA) on three draft guidance documents on biosimilar products.

18 Apr 2012

Imaxio closes EUR 2.9 million funding round

Imaxio, a biopharmaceutical company specialized in the areas of vaccines and genomics, announces today that it has finalized a funding round in which it raised EUR 2.9 million from its principal shareholder, Pradeyrol Developpement.

17 Apr 2012

ImmunoGen commences IMGN529 Phase I trial in NHL

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the start of clinical testing with its IMGN529 product candidate.

17 Apr 2012

FDA grants 510(k) clearance for QIAGEN’s molecular detection PCR technology

QIAGEN N.V. today announced that the U.S. Food and Drug Administration (FDA) has granted two 510(k) clearances for its real-time PCR (polymerase chain reaction) instrument Rotor-Gene Q MDx and a compatible test for the detection of Influenza A/B, the artus Infl A/B RG RT-PCR Kit, for in vitro diagnostic use.

From QIAGEN Manchester Limited 17 Apr 2012

Novasep’s outstanding results in scale-up and biomanufacturing of Apo-A1 acknowledged by Cerenis at BioProcess International Conference

Novasep, a provider of purification-based manufacturing solutions for lifescience molecules, has announced that Cerenis Therapeutics has been invited by BioProcess International to present its major project CER – 001 ApoA1 - HDL mimetic drug candidate, and describe how Novasep played a critical role in the project by successfully achieving the transfer and scale up of Apo-A1 production.

16 Apr 2012

Synthon receives tentative approval for tadalafil tablets

Synthon has announced that its subsidiary Synthon Pharmaceuticals, Inc. has received tentative approval from the U.S. Food and Drug Administration (FDA) for its abbreviated new drug application for tadalafil tablets, 20 mg on April 13, 2012. Synthon's product is a generic and bioequivalent version of Eli Lilly & Co and United Therapeutics’ Adcirca® tablets, which are indicated for the treatment of pulmonary arterial hypertension to improve exercise ability.

16 Apr 2012

Fluidigm begins direct service to customers in China

Fluidigm Corporation has begun direct service to customers in China. Through the establishment of a wholly-owned Fluidigm subsidiary in China in late January 2012, officially known as Fluidigm (Shanghai) Instrument Technology Co., Ltd..

16 Apr 2012

Intelligence may have co-evolved with worry in humans

Worrying may have evolved along with intelligence as a beneficial trait, according to a recent study by scientists at SUNY Downstate Medical Center and other institutions.

16 Apr 2012

Biologists decipher novel functions of metal-binding molecule nicotianamine

In order to survive, plants should take up neither too many nor too few minerals from the soil. New insights into how they operate this critical balance have now been published by biologists at the Ruhr-Universit-t in a series of three papers in the journal The Plant Cell. The researchers discovered novel functions of the metal-binding molecule nicotianamine.

16 Apr 2012

Toxic plants and animal products found in traditional Chinese medicines

A study has found that some traditional Chinese medicines contain potentially poisonous plants, unlabelled ingredients and bits of endangered animals. This has triggered a bid for routine testing and tighter regulation of complementary medicines.

15 Apr 2012

C3BS' new production facilities in Mont-Saint-Guibert granted GMP Certification

The Belgian biotechnology company Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases, today announces that it has been granted Good Manufacturing Practice (GMP) Certification for its new production facilities in Mont-Saint-Guibert.

12 Apr 2012

KineMed receives NIH RAID grant to advance FX-5A for heart disease

KineMed Inc. today announced its successful award of a Rapid Access to Intervention Development (RAID) peer-reviewed grant by the National Institute of Health to advance an HDL mimetic, designated FX-5A, designed to reverse atherosclerosis and heart disease.

12 Apr 2012

Biogen Idec launches FAMPYRA in Canada

Today, Biogen Idec Canada announces that FAMPYRA (fampridine sustained release tablets or fampridine SR) is now available for prescription for patients living with multiple sclerosis (MS) in Canada.

12 Apr 2012